

Date	Time	Track	Presentation Title	Speaker
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Characterization of Anti-HER2 Antibodies Using Advanced Flow Cytometry and BLI Label-Free Detection with Live Q&A	Kirsty McBain Scientist, BioAnalytics Applications Group at Sartorius
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Keynote Presentation: Molecular Pharmacology Profiling: the Precursor to Preclinical Development	Professor Kevin Pfleger, MA, PhD, FBPhS Director, Biomedical and Health Innovation, The University of Western Australia and WA Life Sciences Innovation Hub; President, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT); Head, Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research (Centre for Medical Research, The University of Western Australia); Deputy Director & UWA Node Leader, ARC Centre for Personalised Therapeutics Technologies
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Get Pipetting Right - Tips and Tricks for Accurate and Reproducible Results with Live Q&A	Kate Morgan Regional Business Manager Lab Essentials EMEA, Sartorius
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Using Single B Technology to Develop Lead Antibody Molecules on GPCR Targets with Live Q&A	Donghui Ma, PhD CEO, DIMA Biotechnology LTD
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Panel Presentation: Authenticated and Reproducible Cell Line 'omics Data	Jonathan Jacobs, PhD Senior Director of Bioinformatics, ATCC Telmo Henriques, PhD Scientific Consultant, QIAGEN Digital Insights
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Avoiding InVivo Study Pitfalls	Matthew Flegal, BS, SRS Associate Director, Charles River Laboratories

22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Bridging the Gap - How Human Microphysiological Systems Improve the Translatability of NASH Drug Discovery	Raul Silva Scientist, CN Bio
22-Feb	05:30 - 05:30 AM	New Methods in PK/PD and Pharmacogenomics	Cells, Tox and Rock 'n' Roll - Cell Validation and Drug-Induced Liver Injury Using a Human Liver Microphysiological System	Christiana Skarlatopoulou Scientist, CN-Bio
22-Feb	05:30 - 05:30 AM	New Methods in PK/PD and Pharmacogenomics	Current Use of GPCR Pharmacogenomics in Clinical Practice	Helen E. Smith, PhD Professor, Feik School of Pharmacy, University of the Incarnate Word
22-Feb	-	Biomarker Applications in Clinical Development	Deep Profiling and Spatial Characterization of Tumor Microenvironment (TME) Using Hyperplex Immunofluorescence Assays	Qingyan Sandy Au, PhD, PMP Principal Scientist, Director of Multiplexing Operations, Pharma Services, NeoGenomics Laboratories, Inc.
22-Feb	-	Biomarker Applications in Clinical Development	Innovative Biomarker Spatial Analysis for Comprehensive Tissue Immunophenotyping	Bonnie Phillips, PhD Senior Manager, Global Field Applications Team, Ultivue
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Microplate Reader Detection of a Fluorescent Substrate to Determine Transporter Activity and Identify Novel Inhibitors	Rheaclare Fraser-Spears, PhD Assistant Professor, Department of Pharmaceutical Sciences, University of the Incarnate Word, Feik School of Pharmacy
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Novel Bioassays in Picodroplets for Single-Cell Analysis	Romina Durigon, PhD Senior Field Application Scientist, Sphere Fluidics Limited

22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	PDX/PDO models for Precision Cancer Medicine Beyond Mutations	Nhu-An Pham, PhD Staff Scientist, Princess Margaret Living Biobank (PMLB), University Health Network (UHN)
22-Feb	-	Improved Models in Drug Discovery and Preclinical Development	Preclinical Evaluation of Marine Natural Products for Neuroscience Drug Discovery	Marsha Pierce, PhD Assistant Professor, Department of Pharmacology, Midwestern University
22-Feb	-	Biomarker Applications in Clinical Development	The Many Diagnostic Potentials of Human Neutrophil Lipocalin (HNL)	Per Venge, MD PhD Professor, Department of Medical Sciences, Clinical Chemistry, Uppsala University